BSE filing, NSE: OBEROIRLTY. Summary written from the filing by ALFA Finder's alert engine.
Oberoi Realty Ltd: key numbers
- Share price
- ₹1,601.00
- Market cap
- ₹58,213 Cr
- Revenue (annual)
- ₹6,009 Cr
- Net profit (annual)
- ₹2,507 Cr
- P/E (TTM)
- 22.1×Sector 34.0×
- Promoter holding
- 67.70%+0.00% QoQ
- FII holding
- 15.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Oberoi Realty Ltd
All →Oberoi Realty Debt & Borrowing: ₹12.17 Cr
Oberoi Realty paid Rs.12.17 Crore quarterly interest on its 8.05% NCDs on 26 October 2026. The payment services existing debt and raises no new capital.
- Value
- ₹12.17 Cr
Oberoi Realty Debt & Borrowing: ₹130 Cr
Oberoi Realty partially redeemed Rs.130 Crore of its 8% ORL-8%-22-10-27-PVT NCDs on 23 October 2026. Outstanding amount falls to Rs.150 Crore, with final maturity due 22 October 2027.
- Value
- ₹130.0 Cr
Oberoi Realty Debt & Borrowing: ₹5.65 Cr
Oberoi Realty paid Rs 5.65 crore of quarterly interest on its 8% privately placed NCDs (ORL-8%-22-10-27-PVT). The payment was made on the due date of 23 October 2026.
- Value
- ₹5.65 Cr
Oberoi Realty Earnings Call Transcript: Key Takeaways
Oberoi Realty delivers exceptional Gurgaon entry with ₹8,000 Cr sales, balancing regulatory litigation risks against strong premium demand.
Oberoi Realty Results Update
Oberoi Realty reported financial highlights for Q2FY27 and H1FY27. Consolidated revenue for Q2FY27 stood at Rs. 1,736.37 crores, showing strong operational performance.
Oberoi Realty Merger & Restructuring Worth ₹0.01 Cr
Oberoi Realty Limited approved the incorporation of a new wholly-owned subsidiary. The company will invest Rs. 0.01 Crore as initial paid-up capital.
- Value
- ₹0.01 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.